Concept
Parasite intimately interact with our bodies, evade our immune system, hijack our cells, travel to places they shouldn’t. These skills of parasites demonstrate a ripe chemical space which we could potentially harness to discover new therapeutics.
Longer Description
The success of a therapeutic biomining company focused on parasites will depend on its ability to efficiently identify, adapt, and develop parasitic mechanisms into safe and effective treatments. By leveraging advanced AI techniques similar to those used in modern drug discovery, along with high-throughput screening and synthetic biology, such a company could rapidly explore the vast potential of parasites as a source of novel therapeutics. As our understanding of parasitic biology deepens and technology advances, well-positioned companies in this space have the potential to create entirely new classes of drugs and push therapeutics approaches for a wide range of diseases, particularly those involving the central nervous system, immune modulation, and targeted drug delivery.
Parasites have evolved sophisticated mechanisms to survive and thrive within host organisms, developing abilities that could be revolutionary if applied to human medicine. Examples include:
- Anticoagulants: Leeches produce hirudin, a powerful anticoagulant used to prevent blood clots in patients at risk of heart attacks.
- Immune Modulation: Hookworms and tapeworms release molecules that reduce inflammation, showing potential in treating autoimmune diseases like Crohn's disease.
- Antigenic Variation: Some parasites can change their cellular coating to evade the immune system indefinitely, a mechanism that could inspire new approaches to drug delivery or immune evasion for therapeutic purposes.
- Protein Delivery: Recent research has shown that Toxoplasma gondii can be engineered to transport therapeutic proteins across the blood-brain barrier, opening new possibilities for treating neurological conditions.
Likely a venture-scale company will have a variety of principles including:
- AI-Driven Discovery: Employing machine learning algorithms to predict potential therapeutic applications of parasitic mechanisms and guide research efforts.
- High-Throughput Screening: Developing platforms for rapid testing of parasite-derived molecules and mechanisms.
- Systematic Parasite Screening: Developing methods to identify and characterize potentially useful parasitic mechanisms across a wide range of species.
- Molecular Adaptation: Creating platforms to isolate, modify, and optimize parasitic molecules for therapeutic use while minimizing potential harmful effects.
- Synthetic Biology Integration: Utilizing synthetic biology techniques to recreate and enhance parasitic mechanisms in controlled, non-parasitic organisms.
Other thoughts
- Two separate platforms here for unlocking new chemical space (both small molecule and biologics) OR protein delivery
- Potentially higher capex to get things up and running given higher laboratory safety requirements
- Since this isn’t the biggest area of research, talent constraints for parasitologists will be high
Comparable Companies
- Epeius Pharma - Involved in the development of the T. gondii-based delivery system described in the paper.
Related Reading
